Kyverna Therapeutics And Stanford University Collaborate To Evaluate KYV-101 In Patients With Non-Relapsing And Progressive Forms Of Multiple Sclerosis
Kyverna Therapeutics And Stanford University Collaborate To Evaluate KYV-101 In Patients With Non-Relapsing And Progressive Forms Of Multiple Sclerosis
Kyverna Therapeutics 和斯坦福大學合作評估非復發和進行性多發性硬化症患者的 KYV-101
- The Investigator-Initiated Trial will assess the safety, tolerability, and clinical activity of KYV-101, a fully human anti CD19 CAR T-cell therapy in up to 12 study participants
- The clinical study will be supported by cutting edge correlative studies funded through a parallel research collaboration between Kyverna and Stanford University
- The agreements further expand the scale of ongoing clinical studies assessing the potential therapeutic effects of KYV-101 in multiple diseases and locations around the world
- 這項由研究者發起的試驗將評估 KYV-101（一種全人源抗 CD19 CAR T 細胞療法）在多達 12 名研究參與者中的安全性、耐受性和臨床活性
- 該臨床研究將得到前沿的相關研究的支持，該研究由Kyverna和斯坦福大學之間的平行研究合作資助
- 這些協議進一步擴大了正在進行的臨床研究的規模，這些研究評估 KYV-101 對全球多種疾病和地點的潛在治療作用